We are live on ! Find out more
MCRB icon

Seres Therapeutics

134 hedge funds and large institutions have $256M invested in Seres Therapeutics in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 30 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

551% more call options, than puts

Call options by funds: $6.72M | Put options by funds: $1.03M

77% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.2% less ownership

Funds ownership: 4.39%4.19% (-0.2%)

9% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 23

2% less funds holding

Funds holding: 137134 (-3)

53% less capital invested

Capital invested by funds: $538M → $256M (-$282M)

Holders
134
Holders Change
-3
Holders Change %
-2.19%
% of All Funds
2.13%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
21
Increased
53
Reduced
30
Closed
23
Calls
$6.72M
Puts
$1.03M
Net Calls
+$5.69M
Net Calls Change
-$2.92M

MCRB Hedge Fund Activity: Q3 2023 in Review

134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2023, worth a combined $256M — down 53% from $538M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of MCRB and 21 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 53 added.

The largest buyer was Point72 Asset Management, adding an estimated $6.6M. The largest seller was Janus Henderson Group, cutting an estimated $12.4M.

  • 134 institutional investors held Seres Therapeutics (MCRB) as of Q3 2023, down from 137 in Q2 2023.
  • Funds reported $256M of Seres Therapeutics stock for Q3 2023, down 53% quarter-over-quarter.
  • 21 funds opened new Seres Therapeutics positions in Q3 2023 and 23 closed out, a net change of -2 holders.
  • The largest Seres Therapeutics buyer in Q3 2023 was Point72 Asset Management, an estimated $6.6M added.
  • The largest Seres Therapeutics seller in Q3 2023 was Janus Henderson Group, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2023.